Please login to the form below

Not currently logged in
Email:
Password:

NuPathe

This page shows the latest NuPathe news and features for those working in and with pharma, biotech and healthcare.

Teva suspends migraine patch on burn reports

Teva suspends migraine patch on burn reports

Teva acquired the patch when it bought original developer NuPathe for $114m last year.

Latest news

  • Teva rolls out first migraine patch in US Teva rolls out first migraine patch in US

    The patch was originally developed by NuPathe, which was granted FDA approval for Zecuity in 2013 but delayed a launch until it secured a commercial partner for the product, which some ... Teva acquired rights to it when it bought NuPathe last year,

  • Endo's $2.2bn bid for Auxilium Pharma could thwart QLT deal Endo's $2.2bn bid for Auxilium Pharma could thwart QLT deal

    In the last few months it has also bought NuPathe for $105m - getting hold of migraine patch Zecuity (sumatriptan) - and in June offered $600m for generic player DAVA Pharmaceuticals.

  • FDA approves migraine headband FDA approves migraine headband

    This has meant focus has moved to device-type treatments, including Cefaly and sumatriptan skin patch Zecuity, marketed by pain specialist NuPathe, which is now at the centre of an attempted

  • Teva names Vigodman CEO and makes bid for NuPathe Teva names Vigodman CEO and makes bid for NuPathe

    NuPathe won US approval for its Zecuity (sumatriptan) migraine product last year, when it became the first transdermal patch cleared for the condition. ... NuPathe has been holding off on a launch until it secures a commercial partner.

  • Endo builds pain management business Endo builds pain management business

    Agrees $105m deal to acquire NuPathe. Endo Health Solutions is to acquire NuPathe and its migraine patch treatment in a deal that will see it pay $105m for the US-based ... The move expands Endo's existing pain management business and brings NuPathe's

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Suzanne Gagnon joins Idis as CMO Suzanne Gagnon joins Idis as CMO

    She was most recently chief medical officer at neuroscience company NuPathe, prior to which she spent ten years as chief medical officer at the clinical research organisation (CRO) Icon,.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics